Ning Yang

US Patent:

20220339221, Oct 27, 2022

Filed:

Aug 7, 2020

Appl. No.:

16/988137

Inventors:

- New York NY, US
Stewart SHUMAN - New York NY, US
Jedd WOLCHOK - New York NY, US
Taha MERGHOUB - New York NY, US
Weiyi WANG - New York NY, US
Peihong DAI - New York NY, US
Ning Yang - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

A61K 35/768
C12N 15/86
C07K 16/28
C07K 14/52
A61K 39/395
C07K 14/535
A61K 35/76
A61K 48/00
A61P 35/00

Abstract:

The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

US Patent:

20220186192, Jun 16, 2022

Filed:

Dec 29, 2021

Appl. No.:

17/565332

Inventors:

- New York NY, US
Stewart Shuman - New York NY, US
Ning Yang - New York NY, US
Taha Merghoub - New York NY, US
Jedd Wolchok - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

C12N 7/00
A61P 35/00
A61K 39/285
C12N 15/86

Abstract:

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVAΔC7L and VACVΔC7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVAΔC7L or VACVΔC7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

US Patent:

20230057304, Feb 23, 2023

Filed:

Feb 25, 2022

Appl. No.:

17/681342

Inventors:

- New York NY, US
Stewart SHUMAN - New York NY, US
Jedd WOLCHOK - New York NY, US
Taha MERGHOUB - New York NY, US
Weiyi WANG - New York NY, US
Peihong DAI - New York NY, US
Ning YANG - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

A61K 39/395
A61K 39/00
C12N 15/86
C07K 16/28
C07K 14/52
A61K 35/768
A61P 35/00
A61K 9/00

Abstract:

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.

US Patent:

20200339959, Oct 29, 2020

Filed:

May 11, 2018

Appl. No.:

16/612127

Inventors:

- New York NY, US
Stewart Shuman - New York NY, US
Ning Yang - New York NY, US
Weiyi Wang - New York NY, US
Peihong Dai - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

C12N 7/00
A61K 39/285
C12N 15/86
A61P 35/00

Abstract:

Disclosed herein are methods and compositions related to the treatment, prevention, and/or amelioration of cancer in a subject in need thereof. In particular aspects, the present technology relates to the use of poxviruses, including a recombinant modified vaccinia Ankara (MVA) virus or vaccinia virus with deletion of vaccinia host-range factor C7 (MVAΔC7L and VACVΔC7L, respectively), alone or in combination with immune checkpoint blocking agents, as an oncolytic and immunotherapeutic composition. In some embodiments, the technology of the present disclosure relates to a MVAΔC7L or VACVΔC7L virus further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L).

US Patent:

20200316198, Oct 8, 2020

Filed:

Apr 10, 2020

Appl. No.:

16/845809

Inventors:

- New York NY, US
Stewart SHUMAN - New York NY, US
Jedd WOLCHOK - New York NY, US
Taha MERGHOUB - New York NY, US
Weiyi WANG - New York NY, US
Peihong DAI - New York NY, US
Ning Yang - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

A61K 39/395
A61K 39/00
C12N 15/86
C07K 16/28
C07K 14/52
A61K 35/768
A61P 35/00
A61K 9/00

Abstract:

The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of a recombinant modified vaccinia Ankara (MVA) virus comprising an MVA harboring a human Fms-like tyrosine kinase 3 ligand (hFlt3L) (MVA-hFtl3L). The foregoing vaccinia Ankara (MVA) virus can be delivered to tumor cells of a subject afflicted with a malignant solid tumor, to treat the tumor. In a related aspect, the present disclosure concerns a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MV At.E3L) modified to express human Fins-like 5 tyrosine kinase 3 ligand (hFlt3L) isolated, suitable for use as an immunotherapeutic agent against a malignant solid tumor.

US Patent:

20200237839, Jul 30, 2020

Filed:

Nov 4, 2019

Appl. No.:

16/673475

Inventors:

- New York NY, US
Stewart SHUMAN - New York NY, US
Jedd WOLCHOK - New York NY, US
Taha MERGHOUB - New York NY, US
Weiyi WANG - New York NY, US
Peihong DAI - New York NY, US
Ning YANG - New York NY, US

Assignee:

MEMORIAL SLOAN KETTERING CANCER CENTER - New York NY

International Classification:

A61K 35/768
C07K 16/28
C12N 15/86
A61K 48/00
A61P 35/00
C07K 14/52
A61K 39/395
C07K 14/535
A61K 35/76
A61K 39/00

Abstract:

The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

US Patent:

20190054131, Feb 21, 2019

Filed:

Feb 25, 2017

Appl. No.:

16/079217

Inventors:

- New York NY, US
Stewart SHUMAN - New York NY, US
Jedd WOLCHOK - New York NY, US
Taha MERGHOUB - New York NY, US
Weiyi WANG - New York NY, US
Peihong DAI - New York NY, US
Ning YANG - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

A61K 35/768
A61P 35/00

Abstract:

The present invention relates generally to the fields of oncology, virology and immunotherapy. More particularly, it concerns the use of poxviruses, specifically the replication competent attenuated vaccinia virus with deletion of thymidine kinase (VC-TK) with and without the expression of human Flt3L or GM-CSF as oncolytic and immunotherapy. The foregoing poxviruses can also be used in combination with immune checkpoint blocking agents. The foregoing poxviruses can also be inactivated via Heat or UV-treatment and the inactivated virus can be used as immunotherapy either alone or in combination with immune checkpoint blocking agents.

US Patent:

20190046640, Feb 14, 2019

Filed:

Feb 25, 2017

Appl. No.:

16/079222

Inventors:

- New York NY, US
Stewart SHUMAN - New York NY, US
Jedd WOLCHOK - New York NY, US
Taha MERGHOUB - New York NY, US
Weiyi WANG - New York NY, US
Peihong DAI - New York NY, US
Ning YANG - New York NY, US

Assignee:

Memorial Sloan Kettering Cancer Center - New York NY

International Classification:

A61K 39/395
A61P 35/00
A61K 9/00
A61K 39/00

Abstract:

The present disclosure relates generally to the fields of oncology, virology and immunotherapy. It concerns poxviruses, specifically the highly attenuated modified vaccinia virus Ankara (MVA), and a recombinant modified vaccinia Ankara virus with deletion of vaccinia virulence factor E3 (MVAΔE3L), each further modified to express human Fms-like tyrosine kinase 3 ligand (Flt3L) or GM-CSF. The disclosure relates to use of the foregoing recombinant viruses as cancer immunotherapeutic agents. The foregoing recombinant poxviruses can also be used in combination with immune checkpoint blockade therapy.